TY - JOUR AU - Liu, K. C. AU - Arivajiagane, A. AU - Wu, S. J. AU - Tzou, S. C. AU - Chen, C. Y. AU - Wang, Y. M. PY - 2019 DA - 2019// TI - Development of a novel thermal-sensitive multifunctional liposome with antibody conjugation to target EGFR-expressing tumors JO - Nanomedicine VL - 15 UR - https://doi.org/10.1016/j.nano.2018.10.006 DO - 10.1016/j.nano.2018.10.006 ID - Liu2019 ER - TY - JOUR AU - Zhang, W. AU - Guo, Z. AU - Huang, D. AU - Liu, Z. AU - Guo, X. AU - Zhong, H. PY - 2011 DA - 2011// TI - Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide JO - Biomaterials VL - 32 UR - https://doi.org/10.1016/j.biomaterials.2011.07.071 DO - 10.1016/j.biomaterials.2011.07.071 ID - Zhang2011 ER - TY - JOUR AU - Majumder, J. AU - Taratula, O. AU - Minko, T. PY - 2019 DA - 2019// TI - Nanocarrier-based systems for targeted and site specific therapeutic delivery JO - Adv Drug Deliv Rev VL - 144 UR - https://doi.org/10.1016/j.addr.2019.07.010 DO - 10.1016/j.addr.2019.07.010 ID - Majumder2019 ER - TY - JOUR AU - Blanco, E. AU - Shen, H. AU - Ferrari, M. PY - 2015 DA - 2015// TI - Principles of nanoparticle design for overcoming biological barriers to drug delivery JO - Nat Biotechnol VL - 33 UR - https://doi.org/10.1038/nbt.3330 DO - 10.1038/nbt.3330 ID - Blanco2015 ER - TY - JOUR AU - Mohamed, N. K. AU - Hamad, M. A. AU - Hafez, M. Z. AU - Wooley, K. L. AU - Elsabahy, M. PY - 2017 DA - 2017// TI - Nanomedicine in management of hepatocellular carcinoma: challenges and opportunities JO - Int J Cancer. VL - 140 UR - https://doi.org/10.1002/ijc.30517 DO - 10.1002/ijc.30517 ID - Mohamed2017 ER - TY - JOUR AU - Wakaskar, R. R. PY - 2018 DA - 2018// TI - Promising effects of nanomedicine in cancer drug delivery JO - J Drug Target VL - 26 UR - https://doi.org/10.1080/1061186X.2017.1377207 DO - 10.1080/1061186X.2017.1377207 ID - Wakaskar2018 ER - TY - JOUR AU - Zhang, Y. Q. AU - Shen, Y. AU - Liao, M. M. AU - Mao, X. AU - Mi, G. J. AU - You, C. AU - Guo, Q. Y. AU - Li, W. J. AU - Wang, X. Y. AU - Lin, N. AU - Webster, T. J. PY - 2019 DA - 2019// TI - Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms JO - Nanomedicine VL - 15 UR - https://doi.org/10.1016/j.nano.2018.09.002 DO - 10.1016/j.nano.2018.09.002 ID - Zhang2019 ER - TY - JOUR AU - Aigner, T. B. AU - DeSimone, E. AU - Scheibel, T. PY - 2018 DA - 2018// TI - Biomedical applications of recombinant silk-based materials JO - Adv Mater VL - 30 UR - https://doi.org/10.1002/adma.201704636 DO - 10.1002/adma.201704636 ID - Aigner2018 ER - TY - JOUR AU - Deptuch, T. AU - Dams-Kozlowska, H. PY - 2017 DA - 2017// TI - Silk materials functionalized via genetic engineering for biomedical applications JO - Materials (Basel). VL - 10 UR - https://doi.org/10.3390/ma10121417 DO - 10.3390/ma10121417 ID - Deptuch2017 ER - TY - JOUR AU - Saric, M. AU - Scheibel, T. PY - 2019 DA - 2019// TI - Engineering of silk proteins for materials applications JO - Curr Opin Biotechnol VL - 60 UR - https://doi.org/10.1016/j.copbio.2019.05.005 DO - 10.1016/j.copbio.2019.05.005 ID - Saric2019 ER - TY - JOUR AU - Jastrzebska, K. AU - Kucharczyk, K. AU - Florczak, A. AU - Dondajewska, E. AU - Mackiewicz, A. AU - Dams-Kozlowska, H. PY - 2015 DA - 2015// TI - Silk as an innovative biomaterial for cancer therapy JO - Rep Pract Oncol Radiother VL - 20 UR - https://doi.org/10.1016/j.rpor.2014.11.010 DO - 10.1016/j.rpor.2014.11.010 ID - Jastrzebska2015 ER - TY - JOUR AU - Wicki, A. AU - Witzigmann, D. AU - Balasubramanian, V. AU - Huwyler, J. PY - 2015 DA - 2015// TI - Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications JO - J Control Release VL - 200 UR - https://doi.org/10.1016/j.jconrel.2014.12.030 DO - 10.1016/j.jconrel.2014.12.030 ID - Wicki2015 ER - TY - JOUR AU - Rosenblum, D. AU - Joshi, N. AU - Tao, W. AU - Karp, J. M. AU - Peer, D. PY - 2018 DA - 2018// TI - Progress and challenges towards targeted delivery of cancer therapeutics JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-03705-y DO - 10.1038/s41467-018-03705-y ID - Rosenblum2018 ER - TY - JOUR AU - Wilhelm, S. AU - Tavares, A. J. AU - Dai, Q. AU - Ohta, S. AU - Audet, J. AU - Dvorak, H. F. AU - Chan, W. C. PY - 2016 DA - 2016// TI - Analysis of nanoparticle delivery to tumours JO - Nat Rev Mater. VL - 1 ID - Wilhelm2016 ER - TY - JOUR AU - Bose, R. AU - Molina, H. AU - Patterson, A. S. AU - Bitok, J. K. AU - Periaswamy, B. AU - Bader, J. S. AU - Pandey, A. AU - Cole, P. A. PY - 2006 DA - 2006// TI - Phosphoproteomic analysis of Her2/neu signaling and inhibition JO - Proc Natl Acad Sci USA VL - 103 UR - https://doi.org/10.1073/pnas.0603948103 DO - 10.1073/pnas.0603948103 ID - Bose2006 ER - TY - JOUR AU - Oh, D. Y. AU - Bang, Y. J. PY - 2020 DA - 2020// TI - HER2-targeted therapies—a role beyond breast cancer JO - Nat Rev Clin Oncol VL - 17 UR - https://doi.org/10.1038/s41571-019-0268-3 DO - 10.1038/s41571-019-0268-3 ID - Oh2020 ER - TY - JOUR AU - Wang, J. AU - Xu, B. PY - 2019 DA - 2019// TI - Targeted therapeutic options and future perspectives for HER2-positive breast cancer JO - Signal Transduct Target Ther VL - 4 UR - https://doi.org/10.1038/s41392-019-0069-2 DO - 10.1038/s41392-019-0069-2 ID - Wang2019 ER - TY - JOUR AU - Stagni, V. AU - Manni, I. AU - Oropallo, V. AU - Mottolese, M. AU - Benedetto, A. AU - Piaggio, G. AU - Falcioni, R. AU - Giaccari, D. AU - Carlo, S. AU - Sperati, F. PY - 2015 DA - 2015// TI - ATM kinase sustains HER2 tumorigenicity in breast cancer JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms7886 DO - 10.1038/ncomms7886 ID - Stagni2015 ER - TY - JOUR AU - Moasser, M. M. AU - Krop, I. E. PY - 2015 DA - 2015// TI - The evolving landscape of HER2 targeting in breast cancer JO - JAMA Oncol VL - 1 UR - https://doi.org/10.1001/jamaoncol.2015.2286 DO - 10.1001/jamaoncol.2015.2286 ID - Moasser2015 ER - TY - JOUR AU - Ross, J. S. AU - Gray, G. S. PY - 2003 DA - 2003// TI - Targeted therapy for cancer: the HER-2/neu and Herceptin story JO - Clin Leadersh Manag Rev VL - 17 ID - Ross2003 ER - TY - JOUR AU - Shawver, L. K. AU - Slamon, D. AU - Ullrich, A. PY - 2002 DA - 2002// TI - Smart drugs: tyrosine kinase inhibitors in cancer therapy JO - Cancer Cell VL - 1 UR - https://doi.org/10.1016/S1535-6108(02)00039-9 DO - 10.1016/S1535-6108(02)00039-9 ID - Shawver2002 ER - TY - JOUR AU - Liu, D. AU - Yang, Z. AU - Wang, T. AU - Yang, Z. AU - Chen, H. AU - Hu, Y. AU - Hu, C. AU - Guo, L. AU - Deng, Q. AU - Liu, Y. PY - 2016 DA - 2016// TI - beta2-AR signaling controls trastuzumab resistance-dependent pathway JO - Oncogene VL - 35 UR - https://doi.org/10.1038/onc.2015.58 DO - 10.1038/onc.2015.58 ID - Liu2016 ER - TY - JOUR AU - Herrmann, J. PY - 2020 DA - 2020// TI - Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia JO - Nat Rev Cardiol VL - 17 UR - https://doi.org/10.1038/s41569-020-0348-1 DO - 10.1038/s41569-020-0348-1 ID - Herrmann2020 ER - TY - JOUR AU - Lambert, J. M. AU - Chari, R. V. PY - 2014 DA - 2014// TI - Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer JO - J Med Chem VL - 57 UR - https://doi.org/10.1021/jm500766w DO - 10.1021/jm500766w ID - Lambert2014 ER - TY - JOUR AU - Tang, Y. AU - Soroush, F. AU - Tong, Z. AU - Kiani, M. F. AU - Wang, B. PY - 2017 DA - 2017// TI - Targeted multidrug delivery system to overcome chemoresistance in breast cancer JO - Int J Nanomed VL - 12 UR - https://doi.org/10.2147/IJN.S124770 DO - 10.2147/IJN.S124770 ID - Tang2017 ER - TY - JOUR AU - Belimezi, M. M. AU - Papanastassiou, D. AU - Merkouri, E. AU - Baxevanis, C. N. AU - Mamalaki, A. PY - 2006 DA - 2006// TI - Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment JO - Cancer Immunol Immunother VL - 55 UR - https://doi.org/10.1007/s00262-005-0100-z DO - 10.1007/s00262-005-0100-z ID - Belimezi2006 ER - TY - JOUR AU - Gao, J. AU - Sun, J. AU - Li, H. AU - Liu, W. AU - Zhang, Y. AU - Li, B. AU - Qian, W. AU - Wang, H. AU - Chen, J. AU - Guo, Y. PY - 2010 DA - 2010// TI - Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing JO - Biomaterials VL - 31 UR - https://doi.org/10.1016/j.biomaterials.2009.11.112 DO - 10.1016/j.biomaterials.2009.11.112 ID - Gao2010 ER - TY - JOUR AU - Laginha, K. M. AU - Moase, E. H. AU - Yu, N. AU - Huang, A. AU - Allen, T. M. PY - 2008 DA - 2008// TI - Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer JO - J Drug Target VL - 16 UR - https://doi.org/10.1080/10611860802229978 DO - 10.1080/10611860802229978 ID - Laginha2008 ER - TY - JOUR AU - Park, J. W. AU - Hong, K. AU - Kirpotin, D. B. AU - Colbern, G. AU - Shalaby, R. AU - Baselga, J. AU - Shao, Y. AU - Nielsen, U. B. AU - Marks, J. D. AU - Moore, D. PY - 2002 DA - 2002// TI - Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery JO - Clin Cancer Res VL - 8 ID - Park2002 ER - TY - JOUR AU - Kramer-Marek, G. AU - Kiesewetter, D. O. AU - Martiniova, L. AU - Jagoda, E. AU - Lee, S. B. AU - Capala, J. PY - 2008 DA - 2008// TI - [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography JO - Eur J Nucl Med Mol Imaging VL - 35 UR - https://doi.org/10.1007/s00259-007-0658-0 DO - 10.1007/s00259-007-0658-0 ID - Kramer-Marek2008 ER - TY - JOUR AU - Puri, A. AU - Kramer-Marek, G. AU - Campbell-Massa, R. AU - Yavlovich, A. AU - Tele, S. C. AU - Lee, S. B. AU - Clogston, J. D. AU - Patri, A. K. AU - Blumenthal, R. AU - Capala, J. PY - 2008 DA - 2008// TI - HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents JO - J Liposome Res VL - 18 UR - https://doi.org/10.1080/08982100802457377 DO - 10.1080/08982100802457377 ID - Puri2008 ER - TY - JOUR AU - Bandekar, A. AU - Zhu, C. AU - Gomez, A. AU - Menzenski, M. Z. AU - Sempkowski, M. AU - Sofou, S. PY - 2013 DA - 2013// TI - Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo JO - Mol Pharm VL - 10 UR - https://doi.org/10.1021/mp3002717 DO - 10.1021/mp3002717 ID - Bandekar2013 ER - TY - JOUR AU - Jie, L. Y. AU - Cai, L. L. AU - Wang, L. J. AU - Ying, X. Y. AU - Yu, R. S. AU - Zhang, M. M. AU - Du, Y. Z. PY - 2012 DA - 2012// TI - Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging JO - Int J Nanomed VL - 7 ID - Jie2012 ER - TY - JOUR AU - Wang, X. F. AU - Birringer, M. AU - Dong, L. F. AU - Veprek, P. AU - Low, P. AU - Swettenham, E. AU - Stantic, M. AU - Yuan, L. H. AU - Zobalova, R. AU - Wu, K. PY - 2007 DA - 2007// TI - A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-2480 DO - 10.1158/0008-5472.CAN-06-2480 ID - Wang2007 ER - TY - JOUR AU - Xia, Y. AU - Zhong, J. AU - Zhao, M. AU - Tang, Y. AU - Han, N. AU - Hua, L. AU - Xu, T. AU - Wang, C. AU - Zhu, B. PY - 2019 DA - 2019// TI - Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma JO - Drug Deliv VL - 26 UR - https://doi.org/10.1080/10717544.2018.1556359 DO - 10.1080/10717544.2018.1556359 ID - Xia2019 ER - TY - JOUR AU - Wu, D. AU - Wang, H. AU - Hou, X. AU - Chen, H. AU - Ma, Y. AU - Hou, Y. PY - 2018 DA - 2018// TI - Effects of gold core size on regulating the performance of doxorubicn-conjugated gold nanoparticles JO - Nano Res VL - 11 UR - https://doi.org/10.1007/s12274-017-1963-y DO - 10.1007/s12274-017-1963-y ID - Wu2018 ER - TY - JOUR AU - Reynolds, J. G. AU - Geretti, E. AU - Hendriks, B. S. AU - Lee, H. AU - Leonard, S. C. AU - Klinz, S. G. AU - Noble, C. O. AU - Lucker, P. B. AU - Zandstra, P. W. AU - Drummond, D. C. PY - 2012 DA - 2012// TI - HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity JO - Toxicol Appl Pharmacol VL - 262 UR - https://doi.org/10.1016/j.taap.2012.04.008 DO - 10.1016/j.taap.2012.04.008 ID - Reynolds2012 ER - TY - JOUR AU - Gottesman, M. M. AU - Fojo, T. AU - Bates, S. E. PY - 2002 DA - 2002// TI - Multidrug resistance in cancer: role of ATP-dependent transporters JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc706 DO - 10.1038/nrc706 ID - Gottesman2002 ER - TY - JOUR AU - Schinkel, A. H. AU - Jonker, J. W. PY - 2003 DA - 2003// TI - Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview JO - Adv Drug Deliv Rev VL - 55 UR - https://doi.org/10.1016/S0169-409X(02)00169-2 DO - 10.1016/S0169-409X(02)00169-2 ID - Schinkel2003 ER - TY - JOUR AU - Florczak, A. AU - Mackiewicz, A. AU - Dams-Kozlowska, H. PY - 2014 DA - 2014// TI - Functionalized spider silk spheres as drug carriers for targeted cancer therapy JO - Biomacromol VL - 15 UR - https://doi.org/10.1021/bm500591p DO - 10.1021/bm500591p ID - Florczak2014 ER - TY - JOUR AU - Florczak, A. AU - Jastrzebska, K. AU - Bialas, W. AU - Mackiewicz, A. AU - Dams-Kozlowska, H. PY - 2018 DA - 2018// TI - Optimization of spider silk sphere formation processing conditions to obtain carriers with controlled characteristics JO - J Biomed Mater Res A VL - 106 UR - https://doi.org/10.1002/jbm.a.36516 DO - 10.1002/jbm.a.36516 ID - Florczak2018 ER - TY - JOUR AU - Florczak, A. AU - Jastrzebska, K. AU - Mackiewicz, A. AU - Dams-Kozlowska, H. PY - 2017 DA - 2017// TI - Blending two bioengineered spider silks to develop cancer targeting spheres JO - J Mater Chem B VL - 5 UR - https://doi.org/10.1039/C7TB00233E DO - 10.1039/C7TB00233E ID - Florczak2017 ER - TY - JOUR AU - Jastrzebska, K. AU - Florczak, A. AU - Kucharczyk, K. AU - Lin, Y. AU - Wang, Q. AU - Mackiewicz, A. AU - Kaplan, D. L. AU - Dams-Kozlowska, H. PY - 2018 DA - 2018// TI - Delivery of chemotherapeutics using spheres made of bioengineered spider silks derived from MaSp1 and MaSp2 proteins JO - Nanomedicine VL - 13 UR - https://doi.org/10.2217/nnm-2017-0276 DO - 10.2217/nnm-2017-0276 ID - Jastrzebska2018 ER - TY - JOUR AU - Florczak, A. AU - Mackiewicz, A. AU - Dams-Kozlowska, H. PY - 2019 DA - 2019// TI - Cellular uptake, intracellular distribution and degradation of Her2-targeting silk nanospheres JO - Int J Nanomed VL - 14 UR - https://doi.org/10.2147/IJN.S217854 DO - 10.2147/IJN.S217854 ID - Florczak2019 ER - TY - JOUR AU - Hu, D. AU - Li, T. AU - Xu, Z. AU - Liu, D. AU - Yang, M. AU - Zhu, L. PY - 2018 DA - 2018// TI - Self-stabilized silk sericin-based nanoparticles: In vivo biocompatibility and reduced doxorubicin-induced toxicity JO - Acta Biomater VL - 74 UR - https://doi.org/10.1016/j.actbio.2018.05.024 DO - 10.1016/j.actbio.2018.05.024 ID - Hu2018 ER - TY - JOUR AU - Piechocki, M. P. AU - Pilon, S. A. AU - Wei, W. Z. PY - 2001 DA - 2001// TI - Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2 JO - J Immunol VL - 167 UR - https://doi.org/10.4049/jimmunol.167.6.3367 DO - 10.4049/jimmunol.167.6.3367 ID - Piechocki2001 ER - TY - JOUR AU - Lin, M. C. AU - Lin, Y. C. AU - Chen, S. T. AU - Young, T. H. AU - Lou, P. J. PY - 2017 DA - 2017// TI - Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo JO - BMC Cancer VL - 17 UR - https://doi.org/10.1186/s12885-016-3027-1 DO - 10.1186/s12885-016-3027-1 ID - Lin2017 ER - TY - JOUR AU - Shoji, M. AU - Qian, W. P. AU - Nagaraju, G. P. AU - Brat, D. J. AU - Pessolano, D. AU - Luzietti, R. AU - Chennamadhavuni, S. AU - Yamaguchi, M. AU - Yang, L. AU - Liotta, D. C. PY - 2018 DA - 2018// TI - Inhibition of breast cancer metastasis to the lungs with UBS109 JO - Oncotarget VL - 9 UR - https://doi.org/10.18632/oncotarget.26302 DO - 10.18632/oncotarget.26302 ID - Shoji2018 ER - TY - JOUR AU - Shrestha, N. AU - Lateef, Z. AU - Martey, O. AU - Bland, A. R. AU - Nimick, M. AU - Rosengren, R. AU - Ashton, J. C. PY - 2019 DA - 2019// TI - Does the mouse tail vein injection method provide a good model of lung cancer? JO - F1000Res. VL - 8 UR - https://doi.org/10.12688/f1000research.17964.1 DO - 10.12688/f1000research.17964.1 ID - Shrestha2019 ER - TY - JOUR AU - Arvizo, R. R. AU - Miranda, O. R. AU - Moyano, D. F. AU - Walden, C. A. AU - Giri, K. AU - Bhattacharya, R. AU - Robertson, J. D. AU - Rotello, V. M. AU - Reid, J. M. AU - Mukherjee, P. PY - 2011 DA - 2011// TI - Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles JO - PLoS ONE VL - 6 UR - https://doi.org/10.1371/journal.pone.0024374 DO - 10.1371/journal.pone.0024374 ID - Arvizo2011 ER - TY - JOUR AU - Koyama, Y. AU - Matsui, Y. AU - Shimada, Y. AU - Yoneda, M. PY - 2015 DA - 2015// TI - Biodistribution of gold nanoparticles in mice and investigation of their possible translocation by nerve uptake around the alveolus JO - J Toxicol Sci VL - 40 UR - https://doi.org/10.2131/jts.40.243 DO - 10.2131/jts.40.243 ID - Koyama2015 ER - TY - JOUR AU - Kucharczyk, K. AU - Florczak, A. AU - Deptuch, T. AU - Penderecka, K. AU - Jastrzebska, K. AU - Mackiewicz, A. PY - 2020 DA - 2020// TI - Drug affinity and targeted delivery: double functionalization of silk spheres for controlled doxorubicin delivery into Her2-positive cancer cells JO - J Nanobiotechnology VL - 18 UR - https://doi.org/10.1186/s12951-020-00609-2 DO - 10.1186/s12951-020-00609-2 ID - Kucharczyk2020 ER - TY - JOUR AU - Seib, F. P. AU - Jones, G. T. AU - Rnjak-Kovacina, J. AU - Lin, Y. AU - Kaplan, D. L. PY - 2013 DA - 2013// TI - pH-dependent anticancer drug release from silk nanoparticles JO - Adv Healthc Mater VL - 2 UR - https://doi.org/10.1002/adhm.201300034 DO - 10.1002/adhm.201300034 ID - Seib2013 ER - TY - JOUR AU - Liao, J. AU - Zheng, H. AU - Fei, Z. AU - Lu, B. AU - Zheng, H. AU - Li, D. AU - Xiong, X. AU - Yi, Y. PY - 2018 DA - 2018// TI - Tumor-targeting and pH-responsive nanoparticles from hyaluronic acid for the enhanced delivery of doxorubicin JO - Int J Biol Macromol VL - 113 UR - https://doi.org/10.1016/j.ijbiomac.2018.03.004 DO - 10.1016/j.ijbiomac.2018.03.004 ID - Liao2018 ER - TY - JOUR AU - Liao, J. AU - Zheng, H. AU - Hu, R. AU - Cao, J. AU - Wei, X. AU - Li, D. AU - Zheng, H. AU - Yin, Y. PY - 2018 DA - 2018// TI - Hyaluronan based tumor-targeting and pH-responsive shell cross-linkable nanoparticles for the controlled release of doxorubicin JO - J Biomed Nanotechnol VL - 14 UR - https://doi.org/10.1166/jbn.2018.2510 DO - 10.1166/jbn.2018.2510 ID - Liao2018 ER - TY - JOUR AU - Pan, C. AU - Liu, Y. AU - Zhou, M. AU - Wang, W. AU - Shi, M. AU - Xing, M. AU - Liao, W. PY - 2018 DA - 2018// TI - Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment JO - Int J Nanomed VL - 13 UR - https://doi.org/10.2147/IJN.S147464 DO - 10.2147/IJN.S147464 ID - Pan2018 ER - TY - JOUR AU - Zahmatkeshan, M. AU - Gheybi, F. AU - Rezayat, S. M. AU - Jaafari, M. R. PY - 2016 DA - 2016// TI - Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model JO - Eur J Pharm Sci VL - 86 UR - https://doi.org/10.1016/j.ejps.2016.03.009 DO - 10.1016/j.ejps.2016.03.009 ID - Zahmatkeshan2016 ER - TY - JOUR AU - Mahoney, K. H. AU - Miller, B. E. AU - Heppner, G. H. PY - 1985 DA - 1985// TI - FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor-associated macrophages from metastatic and nonmetastatic mouse mammary tumors JO - J Leukoc Biol VL - 38 UR - https://doi.org/10.1002/jlb.38.5.573 DO - 10.1002/jlb.38.5.573 ID - Mahoney1985 ER -